Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib

Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxol...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Li, Xie, Jundan, Wang, Qian, Shen, Hongjie, Ding, Zixuan, Wen, Lijun, Zeng, Zhao, Xu, Yi, Ruan, Changgeng, Chen, Suning, Xue, Mengxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871410/
https://www.ncbi.nlm.nih.gov/pubmed/36703773
http://dx.doi.org/10.1002/ccr3.6801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871410/
https://www.ncbi.nlm.nih.gov/pubmed/36703773
http://dx.doi.org/10.1002/ccr3.6801

Ejemplares similares